Amino terminal pro brain natriuretic peptide predicts all-cause mortality in patients with chronic obstructive pulmonary disease: Systematic review and meta-analysis

Chronic Respiratory Disease

Volumn 14, Issue 2, 2017, Pages 117-126

  Pavasini, Rita ^a   Tavazzi, Guido ^b,c   Biscaglia, Simone ^a   Guerra, Federico ^d   Pecoraro, Alessandro ^a   Zaraket, Fatima ^a   Gallo, Francesco ^a   Spitaleri, Giosafat ^a   Contoli, Marco ^e   Ferrari, Roberto ^a,f,g   Campo, Gianluca ^a,f,g  

^a UNIVERSITY HOSPITAL OF FERRARA   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

^c FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^d UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^e UNIVERSITY OF FERRARA   (Italy)

^f Laboratorio per le Tecnologie delle Terapie Avanzate   (Italy)

^g MARIA CECILIA HOSPITAL   (Italy)

Author keywords

Chronic obstructive pulmonary disease; exacerbation; mortality; NT proBNP; outcome

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; PEPTIDE FRAGMENT; PRO-BRAIN NATRIURETIC PEPTIDE (1-76);

AGE DISTRIBUTION; ARTICLE; CARDIOVASCULAR DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE EXACERBATION; DISEASE SEVERITY; FORCED EXPIRATORY VOLUME; HEART FAILURE; HUMAN; HYPERTENSION; META ANALYSIS; MORTALITY RATE; PRIORITY JOURNAL; PROGNOSTIC ASSESSMENT; PROTEIN ANALYSIS; PROTEIN FUNCTION; SEX DIFFERENCE; SYSTEMATIC REVIEW; BLOOD; CAUSE OF DEATH; MORTALITY; PREDICTIVE VALUE; PROGNOSIS;

BIOMARKERS; CAUSE OF DEATH; HUMANS; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 85019620504     PISSN: 14799723     EISSN: 14799731     Source Type: Journal    
DOI: 10.1177/1479972316674393     Document Type: Article

References (36)

1. http://www.who.int/mediacentre/factsheets/fs310/en/ (. 2014, accessed 28 December 2015).
2. Maclay JD, MacNee W,. Cardiovascular disease in COPD: mechanisms. Chest 2013; 143: 798-807.
3. Global initiative for chronic obstructive lung disease-global strategy for the diagnosis, management and prevention for chronic obstructive pulmonary disease. Updated 2015, http://www.goldcopd.it/materiale/2015/GOLD-Pocket-2015.pdf (2015, accessed December 2015).
4. Rutten FH, Cramer MJ, Grobbee DE, et al. Unrecognized heart failure in elderly patients with stable chronic obstructive pulmonary disease. Eur Heart J 2005; 26: 1887-1894.
5. Yasue H, Yoshimura M, Sumida H, et al. Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation 1994; 90: 195-203.
6. McMurray JJ, Adamopoulos S, Anker SD, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2012; 14: 803-869.
7. van Gestel YR, Goei D, Hoeks SE, et al. Predictive value of NT-proBNP in vascular surgery patients with COPD and normal left ventricular systolic function. COPD 2010; 7: 70-75.
8. Medina AM, Marteles MS, Sáiz EB, et al. Prognostic utility of NT-proBNP in acute exacerbations of chronic pulmonary diseases. Eur J Intern Med 2011; 22: 167-171.
9. Stamm JA, Belloli EA, Zhang Y, et al. Elevated N-terminal pro-brain natriuretic peptide is associated with mortality in tobacco smokers independent of airflow obstruction. PLoS One 2011; 6: e27416.
10. Chang CL, Robinson SC, Mills GD, et al. Biochemical markers of cardiac dysfunction predict mortality in acute exacerbations of COPD. Thorax 2011; 66: 764-768.
11. Høiseth AD, Omland T, Hagve TA, et al. NT-proBNP independently predicts long term mortality after acute exacerbation of COPD-a prospective cohort study. Respir Res 2012; 13: 97.
12. Marcun R, Sustic A, Brguljan PM, et al. Cardiac biomarkers predict outcome after hospitalisation for an acute exacerbation of chronic obstructive pulmonary disease. Int J Cardiol 2012; 161: 156-159.
13. Campo G, Pavasini R, Malagù M, et al. Relationship between troponin elevation, cardiovascular history and cardiac adverse events in patients with acute exacerbation of COPD. COPD 2015: 12: 560-567.
14. Bernasconi M, Tamm M, Bingisser R, et al. Midregional proatrial natriuretic peptide predicts survival in exacerbations of COPD. Chest 2011; 140 (1): 91-99.
15. Stolz D, Breidthardt T, Christ-Crain M, et al. Use of B-type natriuretic peptide in the risk stratification of acute exacerbations of COPD. Chest 2008; 133 (5): 1088-1094.
16. Moher D, Cook DJ, Eastwood S, et al. Improving the quality of reports of meta-analyses of randomized controlled trials: the QUOROM statement. Lancet 1999; 354: 1896-1900.
17. Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of observational studies in epidemiology (MOOSE) group. JAMA 2000; 283: 2008-2012.
18. Higgins JPT, Green S,. Cochrane handbook for systematic reviews of interventions Version 5.1.0, The cochrane collaboration, 2009., http://handbook.cochrane.org. (. 2011, accessed 28 December 2015).
19. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009; 339: b2700.
20. Wells GA, Shea B, O'Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses., http://www.ohri.ca/programs/clinical-epidemiology/oxford.asp (. accessed 28 December 2015).
21. DerSimonian R, Laird N,. Meta-analysis in clinical trials. Control Clin Trial 1986; 7: 177-188.
22. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557-560.
23. Hilde JM, Skjørten I, Grøtta OJ, et al. Right ventricular dysfunction and remodeling in chronic obstructive pulmonary disease without pulmonary hypertension. J Am Coll Cardiol 2013; 17; 62: 1103-11.
24. Chaouat A, Naeije R, Weitzenblum E,. Pulmonary hypertension in COPD. Eur Respir J 2008; 32: 1371-1385.
25. Campo G, Pavasini R, Malagù M, et al. Chronic obstructive pulmonary disease and ischemic heart disease comorbidity: overview of mechanisms and clinical management. Cardiovasc Drugs Ther 2015; 29: 147-157.
26. Zvezdin B, Milutinov S, Kojicic M, et al. A postmortem analysis of major causes of early death in patients hospitalized with COPD exacerbation. Chest 2009; 136: 376-380.
27. Campo G, Pavasini R, Pollina A, et al. On-treatment platelet reactivity in patients with chronic obstructive pulmonary disease undergoing percutaneous coronary intervention. Thorax 2014; 69 (1): 80-81.
28. Campo G, Guastaroba P, Marzocchi A, et al. Impact of COPD on long-term outcome after ST-segment elevation myocardial infarction receiving primary percutaneous coronary intervention. Chest 2013; 144 (3): 750-757.
29. White JM, Stewart RA,. Troponin elevation during exacerbations of chronic obstructive airways disease due to stress cardiomyopathy. Int J Cardiol 2012; 160: 206-267.
30. Goudis CA, Konstantinidis AK, Ntalas IV, et al. Electrocardiographic abnormalities and cardiac arrhythmias in chronic obstructive pulmonary disease. Int J Cardiol 2015; 199: 264-273.
31. Kara K, Geisel MH, Möhlenkamp S, et al. B-type natriuretic peptide for incident atrial fibrillation-The Heinz Nixdorf Recall Study. J Cardiol 2015; 65: 453-458.
32. García-Berrocoso T, Giralt D, Bustamante A, et al. B-type natriuretic peptides and mortality after stroke: a systematic review and meta-analysis. Neurology 2013; 81 (23): 1976-1985.
33. Wang F, Wu Y, Tang L, et al. Brain natriuretic peptide for prediction of mortality in patients with sepsis: a systematic review and meta-analysis. Crit Care 2012; 16 (3): R74.
34. Pavo N, Raderer M, Hülsmann M, et al. Cardiovascular biomarkers in patients with cancer and their association with all-cause mortality. Heart 2015; 101 (23): 1874-1880.
35. Sivalingam M, Vilar E, Mathavakkannan S, et al. The role of natriuretic peptides in volume assessment and mortality prediction in Haemodialysis patients. BMC Nephrol 2015; 16: 218.
36. Weber M, Hamm C,. Role of B-type natriuretic peptide (BNP) and NT-proBNP in clinical routine. Heart 2006; 92: 843-849.